BioCentury
ARTICLE | Clinical News

FibroGen's pamrevlumab improves survival in Phase I/II for pancreatic cancer

June 15, 2018 4:19 PM UTC

FibroGen Inc. (NASDAQ:FGEN) reported additional data from 37 treatment-naïve patients with locally advanced, unresectable pancreatic cancer in an open-label, U.S. Phase I/II trial showing that pamrevlumab (FG-3019) plus gemcitabine and Abraxane nab-paclitaxel significantly increased median survival in patients who had successful resections vs. gemcitabine and Abraxane alone (40 vs. 18.6 months, p=0.0141). The data were presented at the American Society of Clinical Oncology meeting in Chicago.

In an abstract released ahead of ASCO, FibroGen reported that pamrevlumab plus gemcitabine and Abraxane improved the proportion of patients who underwent resection vs. gemcitabine and Abraxane alone (33.3% vs. 7.7%) (see BioCentury, May 25)...